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Abstract
Background: Body weight and body composition are relevant to the outcomes of cancer and antineoplastic therapy.
However, their role in Phase I clinical trial patients is unknown.
Methods: We reviewed symptom burden, body composition, and survival in 104 patients with advanced cancer referred to
a Phase I oncology service. Symptom burden was analyzed using the MD Anderson Symptom Assessment
Inventory(MDASI); body composition was evaluated utilizing computerized tomography(CT) images. A body mass index
(BMI)$25 kg/m2 was considered overweight. Sarcopenia, severe muscle depletion, was assessed using CT-based criteria.
Results: Most patients were overweight (n = 65, 63%); 53 patients were sarcopenic (51%), including 79% of patients with a
BMI,25 kg/m2 and 34% of those with BMI$25 kg/m2. Sarcopenic patients were older and less frequently African-American.
Symptom burden did not differ among patients classified according to BMI and presence of sarcopenia. Median (95%
confidence interval) survival (days) varied according to body composition: 215 (71–358) (BMI,25 kg/m2; sarcopenic), 271
(99–443) (BMI,25 kg/m2; non-sarcopenic), 484 (286–681) (BMI$25 kg/m2; sarcopenic); 501 d (309–693) (BMI$25 kg/m2;
non-sarcopenic). Higher muscle index and gastrointestinal cancer diagnosis predicted longer survival in multivariate analysis
after controlling for age, gender, performance status, and fat index.
Conclusions: Patients referred to a Phase I clinic had a high frequency of sarcopenia and a BMI$25 kg/m2, independent of
symptom burden. Body composition variables were predictive of clinically relevant survival differences, which is potentially
important in developing Phase I studies.
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Introduction
Several body composition features have been associated with
the incidence, etiology, and therapeutic outcomes of cancer.
Obesity, as one example, has been implicated in the etiology and
prognosis of various cancers [1]. Additionally, weight loss is
frequent among cancer patients, especially in advanced disease
[2], and is the predominant feature of cancer cachexia [3].
Cachexia occurs in up to 80% of cancer patients [4], is a marker of
poor prognosis [5,6,7], negatively impacts patients’ quality of life
[8,9], and impairs their normal physical function [10]. Sarcopenia,
severe muscle depletion, has received special attention in the
recent cancer literature because of its association with reduced
physical ability and increased mortality in noncancer patients
[11,12,13,14], and unfavorable treatment outcomes, especially
severe toxicity [12,15,16]. Studies in patients with malignant
diseases [16,17] and non-malignant conditions [18,19] have
shown that the combination of heavy body weight and sarcopenia
results in particularly poor physical functional ability and clinical
outcome.
Various mechanisms putatively underlie muscle wasting and
cachexia. Inflammation is a likely major player in the genesis of
these entities, and the relationship between cachexia and cytokines has
been widely studied [20,21,22,23,24]. Inflammatory pathways and
cytokines have also been implicated in cancer-related symptoms
[25,26,27,28], which cause severe distress and impair the quality of life
of cancer patients, especially those with advanced disease. A rational
hypothesis is that sarcopenia, cachexia and other cancer-related
symptoms share similar underlying inflammatory mechanisms.
The rapidly developing field of oncology has been driven, in part,
by clinical trials, reflected by the 5,841 active and recruiting oncology
phase I and II studies listed on the www.clinicaltrials.gov website as of
early May 2011. Patients enrolled on these trials typically have failed
to respond to multiple standard-of-care therapeutic regimens and
frequently have less than a one-year expected survival [29]. Ideally,
candidates for accrual to these investigations survive long enough to
generate meaningful results, and have a minimum of features to
confound the interpretation of results (i.e., significant symptom
burden, unusual propensity for treatment toxicity). There is a dearth
of research examining the relationships among body composition, the
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incidence and severity of cancer-related symptoms, and survival in
patients with advanced cancer. Therefore, we assessed these variables
in 104 patients referred to the Phase I clinic at The University of
Texas MD Anderson Cancer Center Department of Investigational
Therapeutics.
Methods
A symptom questionnaire was completed by 124 patients with
advanced cancer who were referred to the Phase I clinic and who
agreed to participate. Patients participating in the study were$18-
years old with documented advanced cancer. The study was
approved by the MD Anderson Institutional Review Board (IRB)
and informed consent was obtained from each patient.
Symptom Inventory
Patients completed the MD Anderson Symptom Inventory
(MDASI) [30], a validated questionnaire used to assess the intensity
of 15 cancer-related symptoms (pain, fatigue, nausea, sleep, distress,
dyspnea, memory, appetite, drowsiness, xerostomia, sadness,
vomiting, numbness, coughing, and constipation). The MDASI
also assesses how patients’ symptoms interfere with six specific life
domains (general activity, mood, normal work, ability to walk,
interpersonal relations, and enjoyment of life). All symptom items
are rated on an 11-point numeric scale from 0 (‘‘no symptom at all’’)
to 10 (‘‘worst imaginable symptom’’). A composite symptom score
ranging from 0 to 10 was computed using the sum of all 15 symptom
scores divided by 15. Interference in the six life domain items was
also rated according to a numeric 11-point scale ranging from 0
(‘‘does not interfere’’) to 10 (‘‘completely interferes’’), and a
composite score was similarly obtained [30].
Demographic Data
Patient demographic data, including age, gender, ethnicity,
cancer diagnosis, height, and weight at the time of presentation to
the Phase I clinic were collected by reviewing the electronic
medical records of the patients assessed in our analysis. When no
information about patient weight was available for specific clinic
appointments, the information was obtained from the closest date
in the patient’s medical chart, which was a median of 5 days before
symptom assessment (range, 1–14). Death date was obtained from
the chart or from the Social Security Death Index for patients
whose medical records did not contain this information [31,32].
Patients with no verifiable death date were censored at the date of
their last follow-up appointment.
Body Composition Assessments
Body mass index (BMI) was calculated by dividing the patient’s
weight in kilograms by height (in meters) squared [33]. Lean body
mass and muscularity were calculated using the validated method
described below.
Computerized tomography (CT) image sets obtained for clinical
purposes no more than 30 days before or after the symptom
questionnaire was filled out were identified by chart review
(median time from image to MDASI, 2 days, interquartile range
1–8 days). Abdominal images at the level of the 3rd lumbar
vertebra (L3) were used for body composition analysis. The 3rd
lumbar vertebra CT cross-sectional image was chosen for analysis
because it contains the following muscles: psoas, erector spinae,
quadratus lumborum, transversus abdominus, rectus abdominus, and the
external and internal oblique muscles, which together are optimal
for estimating lean body mass. The use of the 3rd lumbar vertebra
as the landmark for body composition analysis has been previously
described and validated against dual X-ray absorptiometry and
bioimpedance analysis in healthy populations and in patients with
advanced cancer [34,35,36]. Muscles, subcutaneous fat, and
visceral fat were identified by a single assessor trained in the
specific anatomy of these tissues, demarcated using previously
described Hounsfield unit thresholds [37,38,39] and quantified
Figure 1. Image Acquisition and Analysis. Computerized Tomography images requested for clinical purposes within 30 days of the completion
of the symptom questionnaire (MDASI) were downloaded locally and the different tissues identified at the L3 level. Posteriorly, the cross-sectional
areas determined are applied to regression equations to estimate total body fat and muscle compartments.
doi:10.1371/journal.pone.0029330.g001
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with SliceOMatic software, version 4.3 (Tomovision, Montreal,
QC, Canada). Whole body composition as well as lean and
fat body mass were estimated by applying the values obtained
for muscularity (LBM= lean body mass) and adiposity (FM=
fat mass) at the L3 level to the Mourtzakis et al. for-
mulae: LBM(kg)~0:30|skeletal muscle at L3(cm2)z6:06 and
FM(kg)~0:042|fat tissue at L3(cm2)z11:2 with demonstrated
reliability (r = 0.94, p,0.0001 and r= 0.88, p,0.0001, respectively)
[34]. Patients were considered to be sarcopenic if they had a lumbar
skeletal muscle index (skeletal muscle area at L3 divided by the
height squared) lower than 38.5 cm2/m2 for women and lower than
52.4 cm2/m2 for men, as previously described [16]. This process is
summarized in Figure 1. Fat index was determined by dividing total
adipose tissue area at L3 by the height squared. To further
investigate relationships among BMI, sarcopenia, symptoms, and
survival, we classified patients into 4 groups according to their BMI
(,25 kg/m2 and $25 kg/m2) and the presence or absence of
sarcopenia.
Statistical Analyses
Descriptive statistics were used to summarize our data.
Differences in categorical variables were determined by chi-square
and Fisher’s exact tests, when applicable. Differences in contin-
uous variables were determined by t-tests or by the Mann-Whitney
test, depending on the normality of the data. Differences in
continuous variables across three or more groups were determined
by one-way ANOVA. Survival analyses were done using the
Kaplan-Meier and Cox Regression methods. Significance level
cutoff was 0.05. Analyses were performed using SPSS v. 16.0
computer software (SPSS Inc., Chicago, IL).
Results
Anthropometrical and Body Composition Data
From the initial 124 patients who completed the symptom
questionnaire, evaluable CT images within 30 days of the
completion of the symptom questionnaire were available for 114
Table 1. Anthropometric and demographic data according to BMI and presence/absence of sarcopenia.
Body mass index ,25 kg/m2 $25 kg/m2
Sarcopenia No Yes No Yes P*
n
SEM
(or %) n
SEM
(or %) n
SEM
(or %) n
SEM
(or %)
Age (years) 54.3 2.9 61.0 1.6 56.0 1.9 64.0 1.9 0.012
Gender
Female 3 38% 13 42% 19 44% 4 18% 0.205
Male 5 63% 18 58% 24 56% 18 82%
Race
Caucasian 5 63% 27 87% 32 74% 19 86% 0.062
Hispanic 0 - 2 6% 6 14% 3 14%
African-American 3 38% 1 3% 5 12% 0 -
Other 0 - 1 3% 0 - 0 -
Diagnosis
Gastrointestinal 2 25% 13 42% 12 28% 9 41% 0.825
Head/Neck 3 38% 8 26% 13 30% 7 32%
Others 3 38% 10 32% 18 42% 6 27%
Performance Status
0–1 6 75% 29 94% 39 91% 21 96% 0.336
2–3 2 25% 2 6% 4 9% 1 4%
Body mass index (kg/m2) 23.2 0.5 22.0 0.4 31.6 0.8 28.6 0.7 ,0.001
Skeletal muscle
cross-sectional area (cm2)
150.3 13.0 117.3 5.2 154.6 5.1 136.4 6.1 ,0.001
Intramuscular adipose
cross-sectional area (cm2)
7.5 1.5 8.3 0.8 13.2 1.3 16.1 1.8 ,0.001
Visceral adipose
cross-sectional area (cm2)
29.0 9.3 66.4 9.7 158.1 10.7 180.5 15.8 ,0.001
Subcutaneous adipose
cross-sectional area (cm2)
133.4 18.2 130.8 10.9 292.0 18.8 231.8 19.8 ,0.001
Estimated total lean body mass (kg) 51.1 3.9 41.2 1.6 52.4 1.5 47.0 1.8 ,0.001
Estimated total fat mass (kg) 18.3 1.1 19.8 0.7 30.7 0.9 29.2 0.9 ,0.001
Lumbar skeletal
muscle index (cm2/m2)
50.6 2.9 40.3 1.2 54.1 1.3 44.7 1.4 ,0.001
Lumbar fat index (cm2/m2) 6.3 0.4 7.0 0.3 10.9 0.4 9.7 0.4 ,0.001
* = chi square p value for the first four categories. Otherwise, ANOVA.
doi:10.1371/journal.pone.0029330.t001
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patients (92%) and, of those, 10 (,9%) did not have technically
suitable images (eight had part of the subcutaneous adipose tissue
image cut because of the original imaging framing and two had
extensive surgical procedures changing the usual anatomy of the
L3 level images). Of the 104 evaluable patients, 53 were
sarcopenic (51%). The difference in rate of sarcopenia did not
attain statistical significance in men versus women (55% vs. 44%,
p= 0.312). Overall, patients$65 years were more likely to be
sarcopenic (25/35, 71% vs. 28/69, 41%, p= 0.003) and African
Americans were less likely to be sarcopenic (1/9, 11% vs. 52/95,
55%, p= 0.015). Sarcopenia was present in 31/38 (79%) of
patients with a BMI,25 kg/m2 and in 22/65 (34%) of patients
with a BMI$25 kg/m2 (p,0.0001). Underweight patients
(BMI#18.5 kg/m2) accounted for only approximately 3% of the
study population (3 patients). Therefore, they were grouped with
the normal weight patients for all analyses.
Body composition and anthropometrical features are reported
in Table 1. Significant differences were detected among the four
groups (BMI,25 kg/m2 non-sarcopenic, BMI,25 kg/m2 sarco-
penic, BMI$25 kg/m2 non-sarcopenic, and BMI$25 kg/m2
sarcopenic) with regards to all anthropometrical features and
body composition.
Body Composition and Survival
Overall median survival (95% confidence interval), assessed
from the date when the initial CT image was obtained, was 400
days (range, 270–530). There was a trend towards shorter median
survival among sarcopenic compared to non-sarcopenic patients
(304 days [range, 201–406] versus 474 days [range, 346–601]),
respectively, but the difference did not attain statistical significance
(p = 0.151). Patients#65 years with sarcopenia had significantly
shorter survivals compared to patients without sarcopenia (301
versus 487 days, respectively, p = 0.042).
Survival differed across the four groups according to BMI and
presence of sarcopenia, as depicted in Figure 2. Patients with a
BMI,25 kg/m2 with sarcopenia had the shortest survival (median
215 days, 95% confidence interval 99–443 days), whereas patients
with a BMI$25 kg/m2 without sarcopenia fared best (median
survival 501 days, 95% confidence interval 309–693 days, log-rank
p= 0.013).
After controlling for the effects of age, gender, performance
status, and fat index in multivariate analysis, patients with higher
muscle indices had longer survivals (hazard ratio 0.955, confidence
interval 0.923–0.989, p= 0.009), as did those with gastrointestinal
malignancies, with a hazard ratio of death of 0.509 (confidence
interval 0.307–0.845, p= 0.009) (Table 2).
Symptom Burden
Overall symptom burden is described in Table 3. Fatigue was
the most frequently reported symptom (93/104 patients, 90%) and
vomiting was the least reported (25/104 patients, 24%).
No statistically significant differences in symptom burden were
found among the four groups according to BMI and presence of
sarcopenia. Symptom severity was generally low, with an average
composite score of 2.1 (standard error 60.14). The MDASI
interference scores are shown in Table 4. There was a low degree
of interference with all six life domains. No statistically significant
differences were found among the four groups according to BMI
and presence of sarcopenia. However, patients with sarcopenic
obesity (sarcopenia and BMI$30 kg/m2) reported greater mean
interference scores for mood compared to patients without
sarcopenic obesity (mean 6 standard error 4.461.2 versus
2.160.20, respectively, p,0.05).
Discussion
When patients are enrolled on clinical trials of investigational
agents or regimens, they are monitored closely for side effects, and
trial endpoints typically include toxicity and survival assessments
[40,41]. Patients with cancer participating in such trials have
usually failed several lines of standard treatment and have
advanced disease. Their expected survival is relatively short [29]
and they often suffer from diverse symptoms [42]. Cachexia is a
frequent complication of cancer, and the interrelationship between
symptom burden, body composition, and survival may play a role
in how patients tolerate treatment drugs and their outcome. Yet,
very little is known about these interrelationships. Previously, other
groups have studied distinct potential predictors of clinical
outcomes in the Phase I setting. Italiano and collaborators have
observed in a sample of 180 patients enrolled into Phase I trials
that time between cancer diagnosis and enrollment in the clinical
trial greater or equal to 24 months and evidence of treatment
response were predictors of greater overall survival [43]. Arkenau
and collaborators showed that overall survival of 212 patients
enrolled in oncology Phase I trials could be predicted by a score
(the Royal Marsden Hospital - RMH score) that included albumin
greater than 35 g/L, lactate dehydrogenase greater than the upper
limit of normality, and two or more sites of metastases [44]. The
RMH score has been independently validated by our group in a
sample of 229 patients enrolled in Phase I trials [45]. The current
study is a preliminary assessment of the associations among body
composition, symptom burden and survival in 104 patients with
advanced cancer referred to the Phase I clinic at MD Anderson.
We focused on the body composition aspect of sarcopenia
because it has been associated with shorter survival in cancer
patients, and seems be a central factor in the genesis of
chemotherapy toxicity [15,16]. We found a 51% frequency of
sarcopenia in our patients. This can be compared to a small
number of published reports on patients with solid tumors. For
Figure 2. Kaplan-Meier curves of the four groups of patients.
Survival analyses were performed using Kaplan-Meier curves and log-
rank tests to detect differences in survival among the four groups of
patients (normal weight non-sarcopenic, normal weight sarcopenic,
overweight non-sarcopenic, and overweight sarcopenic patients.
Patients who are alive at last known follow up are censored at that date.
doi:10.1371/journal.pone.0029330.g002
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instance, Prado et al., in a study of 250 obese patients with
respiratory and gastrointestinal cancers, reported that the
proportion of sarcopenic patients was 15% [16]. Similarly, we
found that 29% of our patients were obese (BMI$30 kg/m2) and
17% (5/30) of our obese patients were sarcopenic. Antoun et al.
recently showed in a study of 80 patients with advanced renal cell
carcinoma, a frequency of sarcopenia of 72% among patients with
a BMI,25 kg/m2 and 34% in patients with a BMI$25 kg/m2,
similar to our findings of 79% and 34%, respectively [46]. The
Prado group reported sarcopenia in 25% of 55 women with
metastatic breast cancer receiving capecitabine [15], which is
lower than our finding of sarcopenia in 44% of women (17/39). In
a comparable sample of 111 patients with advanced pancreatic
cancer receiving palliative chemotherapy, Tan et al. observed a
56% prevalence of sarcopenia [17], which is similar to the 51%
overall prevalence in our study population.
We also observed a trend towards sarcopenia being more
common in older patients consistent with previous reports
demonstrating that sarcopenia is more prevalent among the
elderly. This relationship is not surprising since muscle loss is a
process normally associated with aging [23,47,48,49]. Additional-
ly, we found that African American individuals were less
frequently sarcopenic than others. This finding is consistent with
previously reported data from a large population (N= 3,000)
showing that African Americans had a greater proportion of lean
body mass than other racial groups [50].
Overall, our patients reported symptoms that were mild in
intensity (mean composite symptom score of ,2.0), a value similar
to that described by Finlay et al. in a Phase I population [42] The
relatively low symptom burden may be attributable to the strict
eligibility requirements for many early phase clinical trials, leading
to referral for clinical trial participation of patients with a good
Table 3. MDASI scores – The MDASI includes questions about 15 symptoms frequent in advanced cancer patients.
BMI,25 kg/m2 BMI$25 kg/m2
Symptoms Non-sarcopenic Sarcopenic Non-sarcopenic Sarcopenic ANOVA p
Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM)
Pain 2.6 (0.7) 2.8 (0.5) 2.3 (0.4) 2.2 (0.6) 0.822
Fatigue 4.1 (0.6) 4 (0.5) 3.4 (0.4) 4.3 (0.6) 0.605
Nausea 1.4 (1) 1.8 (0.5) 1.7 (0.4) 1.2 (0.5) 0.843
Insomnia 1.5 (0.8) 2.8 (0.5) 2.3 (0.4) 2.9 (0.6) 0.536
Distress 2.6 (1) 1.5 (0.3) 2.7 (0.4) 2.5 (0.6) 0.208
Dyspnea 2.3 (0.9) 2.1 (0.5) 1.5 (0.3) 1.7 (0.6) 0.696
Memory loss 1.6 (0.5) 2 (0.4) 2 (0.4) 2.8 (0.5) 0.592
Anorexia 1.9 (1.1) 2.8 (0.6) 2 (0.5) 1.7 (0.5) 0.557
Drowsiness 2.9 (0.8) 2.5 (0.5) 2.5 (0.4) 3 (0.5) 0.818
Dry mouth 2.8 (1.3) 2.2 (0.4) 2 (0.4) 3 (0.7) 0.475
Sadness 1.6 (0.9) 1.2 (0.3) 2.1 (0.5) 2 (0.4) 0.458
Vomiting 1.4 (1) 0.9 (0.3) 1.1 (0.4) 0.5 (0.4) 0.685
Numbness 2.3 (1) 2.2 20.5 1.3 (0.3) 2.2 (0.4) 0.268
Coughing 1.4 (0.8) 1.1 (0.3) 1.8 (0.4) 1.1 (0.5) 0.531
Constipation 1.8 (0.7) 1.6 (0.4) 1.2 (0.3) 2 (0.7) 0.549
Symptom composite 2.1 (0.5) 2.1 (0.2) 2 (0.2) 2.2 (0.3) 0.952
Patients grade their symptoms on a 0–10 scale in which 0 represents ‘‘no symptom at all’’ and 10 represents ‘‘worst symptom imaginable’’. Mean symptom scores and
standard error of the means (SEM) are presented.
doi:10.1371/journal.pone.0029330.t003
Table 2. Predictors of survival – multivariate analysis.
Univariate analyses* Multivariate analysis**
Hazard Ratio CI p value Hazard Ratio CI p value
Age 1.004 0.982–1.026 0.720 - - -
Female gender 0.962 0.568–1.628 0.885 0.710 0.492–1.024 0.067
Performance status 1.514 1.030–2.226 0.035 1.458 0.974–2.184 0.067
Diagnosis (GI vs. others) 0.445 0.270–0.735 0.002 0.509 0.307–0.845 0.009
Muscle Index 0.974 0.951–0.998 0.036 0.955 0.923–0.989 0.009
Fat index 0.921 0.835–1.015 0.098 - - -
*Cox Univariate analyses.
**Backward elimination method of Cox Proportional Hazards Model.
doi:10.1371/journal.pone.0029330.t002
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performance status, despite having advanced disease. No statisti-
cally significant differences in symptom intensity or interference
with function were detected when we compared symptom burden
across the four combinations of BMI (cutoff 25 kg/m2) and
sarcopenia (present/absent).
Overall survival from the time that imaging studies were initially
obtained for our patients was ,13 months. Patients who were
overweight (BMI$25 kg/m2) but without sarcopenia fared best,
with an approximately 130% longer median survival compared to
patients with a BMI,25 kg/m2 with sarcopenia (median survival
501 vs. 215 days, respectively). The feature of sarcopenia in lower
body weight patients predicts an atypically short survival in
patients otherwise meeting the criteria for Phase I trials.
Conversely, heavy body weight was associated with a longer
median survival. A so-called ‘‘obesity paradox’’ is described, albeit
poorly understood, in cardiovascular diseases [51] and renal
insufficiency [52,53], conditions in which patients with higher
body mass indices seem to survive longer. In the cancer setting,
overweight patients may only apparently survive longer because
individuals who are impacted most by their disease lose weight and
are classified as having normal weight or even as being
underweight, depending on their baseline status. Previous studies
have repeatedly showed that sarcopenia has a negative impact on
survival. For example, Tan et al. recently demonstrated that
sarcopenia is a poor prognostic factor among overweight and
obese patients with pancreatic cancer [17]. A similar finding was
reported by Prado et al. in a study that included patients with
gastrointestinal and respiratory cancers and concurrent obesity
[16].
In conclusion, sarcopenia occurred frequently in our patients
with advanced cancer referred for clinical trials. Younger age,
African American race, and overweight patients (BMI$25 kg/m2)
were less likely to be sarcopenic. Although there was a trend for
sarcopenic patients to have an increased symptom burden, it did
not reach statistical significance. Further, although sarcopenic
patients had a six-month shorter average survival than non-
sarcopenic patients, this trend was not statistically significant,
except in patients less than 65 years old (p = 0.042). Multivariate
analysis showed that muscle index was an independent prognostic
factor, with patients having greater muscularity faring better.
Patients who did the best had a BMI$25 kg/m2 and were non-
sarcopenic, and those who fared worst had a BMI,25 kg/m2 and
were sarcopenic. These data suggest that sarcopenia, weight and
other body composition variables merit further study to determine
their predictive value in populations of cancer patients being
considered for Phase I trial participation and may help better
characterize and redefine existing prognostic indices for Phase I
settings.
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